Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its metabotropic glutamate receptor type III positive allosteric modulators program. The MJFF first supported the initial stages of this program in 2012 through a 300 000 dollars (USD) grant.
NEW GRANT FOR DOMAIN THERAPEUTICS
This entry was posted in Non classé. Bookmark the permalink. Both comments and trackbacks are currently closed.
